Dalteparin did not reduce the incidence of the primary composite outcome in both intention-to-treat analysis ( dalteparin @/@ -LSB- @ % ; @ % CI @-@ % -RSB- vs no dalteparin @/@ -LSB- @ % ; @ % CI @-@ % -RSB- ; risk difference -@ % -LSB- @ % CI -@ % to @ % ) ) and on-treatment analysis ( dalteparin @/@ -LSB- @ % -RSB- vs no dalteparin @/@ -LSB- @ % -RSB- ; risk difference +@ % -LSB- @ % CI -@ to @ % -RSB- ) .